• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Sleepwalking on Antipsychotics and Lithium

Sleepwalking on Antipsychotics and Lithium

November 5, 2021
Thomas Jordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Gouverneur A et al, Br J Clin Pharmacol 2021;87:3971–3977


STUDY TYPE: Retrospective analysis


Sleepwalking and sleep-eating are common parasomnias, also known as somnambulism and sleep-related eating disorder. Both can be side effects of benzos, z-hypnotics, and—rarely—antidepressants. This review looked at parasomnias’ association with antipsychotics and lithium.


The authors used a World Health Organization database of suspected adverse drug reactions, which contains reports by physicians dating back to 1978. Lacking a control group, they compared the rate of parasomnias in the database with that in the general population to see if there was any disproportional reporting for patients on atypical antipsychotics or lithium.


They presented their data in terms of the proportional reporting ratio (PRR) for each medication—where a PRR over 1 means the parasomnia might be associated with the medication. As expected, the highest PRR by far was for the benzodiazepines and z-drugs, together at 60.51. The PRRs were also elevated for the atypical antipsychotics at 3.44 (CI 3.13–3.78) and lithium at 2.03 (CI 1.22–3.37). First-generation antipsychotics did not show a significant PRR at 0.99 (0.68–1.44), while antidepressants clocked in at 3.01 (CI 2.76–3.28). Atypical antipsychotics with the highest PRRs were quetiapine at 12.50 (CI 11.06–14.13), lurasidone at 7.00 (CI 3.97–12.34), olanzapine at 3.23 (CI 2.50–4.17), and aripiprazole at 2.89 (CI 2.17–3.83). Of the atypical antipsychotics, nearly all had a significant PRR except for risperidone, paliperidone, and clozapine.


The main weakness here is that data of this type are meant to find associations but cannot confirm them. Also, the results do not tell us how common the problem is, as mild cases are usually not reported to these kinds of databases.


TCPR’S Take
Although benzodiazepines and z-hypnotics are the medications that are most likely to cause parasomnias, these sleep problems may also occur on antidepressants, lithium, and most atypical antipsychotics.

General Psychiatry
KEYWORDS antipsychotics lithium second-generation-antipsychotics-sgas side-effects sleep sleep_disorders somnambulism
    Thomas Jordan, MD.

    Methylphenidate Max Dosing

    More from this author
    www.thecarlatreport.com
    Issue Date: November 5, 2021
    SUBSCRIBE NOW
    Table Of Contents
    How to Treat ADHD in Bipolar Disorder
    In the News: Aducanumab (Aduhelm)
    Viloxazine for ADHD
    Listening to Depression: The Importance of Addressing Hearing Loss
    Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia
    Sleepwalking on Antipsychotics and Lithium
    In Brief: Meds in the Fast Lane
    How to Diagnose Bipolar Disorder
    Nutritional Psychiatry in Practice
    CME Post-Test - Bipolar Disorder, TCPR, November/December 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.